You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
NeoDynamics – Presentation of Q2 2023
Meet and ask questions to CEO Anna Eriksrud and CFO Aaron Wong from NeoDynamics – Tuesday 1 August at 4:15 PM CEST
CEO Anna Eriksrud will briefly update the investor community on the commercial development in US and Europe, and CFO Aaron Wong will run through the figures and the details regarding the rights issue.
NeoDynamics will release Q2 figures on 31 July.
NeoDynamics AB (publ) is a Swedish medical technology company dedicated to advancing the diagnostics and treatment of cancer. The company has created an innovative biopsy system called NeoNavia®. This biopsy system builds on a patented pulse technology based on research at the Karolinska Institutet in Sweden. The innovative pulse biopsy system is designed to offer clinicians and patients reliable tissue sampling with high tissue yield for correct diagnosis and individualized treatment. NeoNavia has been launched in the Swedish, German, and British markets. NeoDynamics is listed on Nasdaq’s First North Growth Market in Stockholm.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 11:45 AM CEST – 04/07/2023.